London, United Kingdom, November 07, 2019 --(PR.com)-- SMi Group is delighted to announce the return of the successful Superbugs & Superdrugs Conference for its 22nd year, taking place on 30 and 31 March 2020 at the Holiday Inn Kensington Forum in London. Antibiotics have long been one of the most important pharmaceuticals for maintaining public health, however, there has been a recent pressing need for significant progress within the industry, mainly due to indiscriminate use of antibiotics which has caused bacteria to become resistant to colistin, carbapenems and 3rd and 4th generation cephalosporins.

This year, the two-day agenda will focus on novel drugs and approaches, highlighting non-traditional and traditional therapies that provide an innovative means to tackle the continued rise of antibiotic resistance, while placing significant emphasis on the much-needed support for these innovations.

For those interested in attending, there is an early bird offer with a �400 saving for bookings made by 29 November 2019, visit www.superbugssuperdrugs.com/PR1 to register.

Key Featured speakers include:

- Yuri Gleba, Professor, Founder, Nomad Bioscience
- Mark Albrecht, Branch Chief, Antibacterials Program, BARAD/HHS
- Paul Finn, CEO, Oxford Drug Design
- Cara Cassino, Chief Medical Officer, Contrafect
- Martin Everett, CSO, Antabio
- Samareh Lajaunias, Director, Combioxin SA
- Francois Moreau, Scientific Director, Mutabilis
- Emma Leire, Microbiology Lead, Centauri Therapeutics
- Lorenzo Corsini, Co-Founder/CEO/R&D, Phagomed
- Stephen Barat, VP, Preclinical Research and Early Development, Scynexis
- Colm Leonard, Consultant Clinical Adviser/Consultant Thoracic Physician/Honorary Pro

Topics covered will include:

- Discuss the new classes of non-antibiotic antibacterial proteins: Colicins and Colicin-like Bacteriocins from Nomad Bioscience
- Gain valuable insight towards fighting severe and resistant infections through neutralising bacterial virulence effectors from Combioxin
- Examine a UK project looking at novel value assessment and reimbursement for novel antimicrobials from NICE/Manchester University NHS Foundation Trust
- Explore direct lytic agents (DLAs) and their potential as a successful disruptive anti-infective technology with Contrafect
- Evaluate the utility of machine learning and AI in antibiotic drug discovery with Oxford Drug Design

In addition to the agenda, there will be two half-day interactive workshops held on 1 April 2020. Workshop A on Development of Non-Traditional Agents and Alternatives to Antibiotics will be held in the morning, led by Peter Warn, SVP Anti-infective Discovery, Evotec (UK) Ltd., where the workshop will explore the development of agents � specifically, how they kill or don�t kill microbes, or alter the host.

Workshop B on Anti-Microbial Resistance and Pathogenic Fungi will be held in the afternoon, led by Stephen Barat, Vice President, Preclinical Research and Early Development, Scynexis. The workshop will explore anti-microbial resistance in the fungal arena, resistance in candida SPP and other pathogenic fungi, as well as discuss the challenges in treating MDR strains and the need for new anti-fungal drugs.

The full agenda and speaker line-up brochure is available to download online at www.superbugssuperdrugs.com/PR1

For sponsorship enquiries contact Alia Malick on +44 (0)20 7827 6164 or [email protected]

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or [email protected]

Superbugs & Superdrugs 2020
Conference: 30 � 31 March 2020
Holiday Inn Kensington Forum, London, UK
www.superbugssuperdrugs.com/PR1
#SMiBugs